Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): a state-of-the-art report on behalf of the International Consortium for MDS (icMDS)

Journal article : Review

The guidelines for classification, prognostication, and response assessment of myelodysplastic syndromes/neoplasms (MDS) have all recently been updated. In this report on behalf of the International Consortium for MDS (icMDS) we summarize these developments. We first critically examine the updated World Health Organization (WHO) classification and the International Consensus Classification (ICC) of MDS. We then compare traditional and molecularly based risk MDS risk assessment tools. Lastly, we discuss limitations of criteria in measuring therapeutic benefit and highlight how the International Working Group (IWG) 2018 and 2023 response criteria addressed these deficiencies and are endorsed by the icMDS. We also address the importance of patient centered care by discussing the value of quality-of-life assessment. We hope that the reader of this review will have a better understanding of how to classify MDS, predict clinical outcomes and evaluate therapeutic outcomes.

Authors: Stahl, M; Bewersdorf, JP; Xie, Z; Porta, MGD; Komrokji, R

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Elsevier
• Journal: Blood Reviews
• Volume: 62
• Article number: 101128
• Publication date: 2023-08-19
• Acceptance date: 2023-08-16
• DOI: 10.1016/j.blre.2023.101128
• EISSN: 1532-1681
• ISSN: 0268-960X
• Pmid: 37704469
• Language: English
• Keywords: prognosis; myelodysplastic syndromes; quality of life; humans; FFR; risk assessment; neoplasms
• Subtype: Review